Oridonin: targeting programmed cell death pathways as an anti-tumour agent

被引:60
|
作者
Liu, Z. [2 ]
Ouyang, L. [3 ,4 ]
Peng, H. [1 ]
Zhang, W. -Z. [2 ]
机构
[1] BeiGene Beijing Co Ltd, Beijing 102206, Peoples R China
[2] Gen Hosp PLA, Dept Hepatobiliary Surg, Beijing 100853, Peoples R China
[3] Sichuan Univ, W China Hosp, State Key Lab Biotherapy, Chengdu 610064, Peoples R China
[4] Sichuan Univ, W China Hosp, Ctr Canc, Chengdu 610064, Peoples R China
关键词
SIGNAL-REGULATED KINASE; FIBROSARCOMA L929 CELLS; CYTOCHROME-C RELEASE; CARCINOMA HELA-CELLS; APOPTOTIC U937 CELLS; NF-KAPPA-B; IN-VITRO; ENHANCED PHAGOCYTOSIS; INDUCED AUTOPHAGY; TRANSDUCTION PATHWAYS;
D O I
10.1111/j.1365-2184.2012.00849.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Oridonin, an active diterpenoid isolated from traditional Chinese herbal medicine, has drawn rising attention for its remarkable apoptosis- and autophagy-inducing activity and relevant molecular mechanisms in cancer therapy. Apoptosis is a well known type of cell death, whereas autophagy can play either pro-survival or pro-death roles in cancer cells. Accumulating evidence has recently revealed relationships between apoptosis and autophagy induced by oridonin; however, molecular mechanisms behind them remain to be discovered. In this review, we focus on highlighting updated research on oridonin-induced cell death signalling pathways implicated in apoptosis and autophagy, in many types of cancer. In addition, we further discuss cross-talk between apoptosis and autophagy induced by oridonin, in cancer. Taken together, these findings open new perspectives for further exploring oridonin as a potential anti-tumour agent targeting apoptosis and autophagy, in future anti-cancer therapeutics.
引用
收藏
页码:499 / 507
页数:9
相关论文
共 50 条
  • [41] Glutarate regulates T cell metabolism and anti-tumour immunity
    Minogue, Eleanor
    Cunha, Pedro P.
    Wadsworth, Brennan J.
    Grice, Guinevere L.
    Sah-Teli, Shiv K.
    Hughes, Rob
    Bargiela, David
    Quaranta, Alessandro
    Zurita, Javier
    Antrobus, Robin
    Velica, Pedro
    Barbieri, Laura
    Wheelock, Craig E.
    Koivunen, Peppi
    Nathan, James A.
    Foskolou, Iosifina P.
    Johnson, Randall S.
    NATURE METABOLISM, 2023, 5 (10) : 1747 - 1764
  • [42] Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
    Samson, Adel
    Bentham, Matthew J.
    Scott, Karen
    Nuovo, Gerard
    Bloy, Abigail
    Appleton, Elizabeth
    Adair, Robert A.
    Dave, Rajiv
    Peckham-Cooper, Adam
    Toogood, Giles
    Nagamori, Seishi
    Coffey, Matthew
    Vile, Richard
    Harrington, Kevin
    Selby, Peter
    Errington-Mais, Fiona
    Melcher, Alan
    Griffin, Stephen
    GUT, 2018, 67 (03) : 562 - 573
  • [43] Programmed Cell Death Pathways and Current Antitumor Targets
    Mei Lan Tan
    Jer Ping Ooi
    Nawfal Ismail
    Ahmed Ismail Hassan Moad
    Tengku Sifzizul Tengku Muhammad
    Pharmaceutical Research, 2009, 26 : 1547 - 1560
  • [44] Targeting Bid to prevent programmed cell death in neurons
    Culmsee, C.
    Plesnila, N.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2006, 34 : 1334 - 1340
  • [45] Targeting the programmed cell death pathway for cancer treatment
    Clarke, MF
    Qian, D
    Han, J
    Nunez, G
    Wicha, M
    CANCER GENE THERAPY, 1999, 6 (06) : S1 - S1
  • [46] ANTI-TUMOUR EFFECTS OF INTERFERON AND ITS POSSIBLE USE AS AN ANTI-NEOPLASTIC AGENT IN MAN
    STRANDER, H
    TEXAS REPORTS ON BIOLOGY AND MEDICINE, 1977, 35 : 429 - 435
  • [47] Programmed Cell Death Pathways and Current Antitumor Targets
    Tan, Mei Lan
    Ooi, Jer Ping
    Ismail, Nawfal
    Moad, Ahmed Ismail Hassan
    Muhammad, Tengku Sifzizul Tengku
    PHARMACEUTICAL RESEARCH, 2009, 26 (07) : 1547 - 1560
  • [48] Cell-mediated anti-tumour immunity and implications for immunotherapy
    Guillet, JG
    Buzyn, A
    Le Gal, FA
    Ostankovitch, M
    HEMATOLOGY AND CELL THERAPY, 1998, 40 (02): : 92 - 95
  • [49] Targeting Programmed Cell Death 1 in Ovarian Cancer
    Homicsko, Krisztian
    Coukos, George
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 3987 - +
  • [50] TAMOXIFEN AS AN ANTI-TUMOUR AGENT - ESTROGEN BINDING AS A PREDICTIVE TEST FOR TUMOR RESPONSE
    JORDAN, VC
    JASPAN, T
    JOURNAL OF ENDOCRINOLOGY, 1976, 68 (03) : 453 - 460